This is a review of an integrated analysis of five clinical trials that evaluated the efficacy and safety of romiplostim self-administration.
The studies involved over 1100 patients and commentary is provided by Dr Danny Hsu, a consultant clinical and laboratory haematologist at Liverpool Hospital. He is also the Director of Therapeutic Apheresis and the Clinical Lead for Immune Haematology.
Please login below to download this issue (PDF)